REGN

2 Reasons to Buy Regeneron Stock Like There's No Tomorrow

12/13 11:01 am

Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

12/08 09:00 am

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

12/07 05:30 pm

Is Alnylam Pharmaceuticals a Millionaire Maker?

12/07 03:25 am

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

12/01 08:00 am

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?

12/01 12:15 am

Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider

11/28 01:28 am

Asthma and COPD Medicines Market Size to Lead USD 19.32 Bn by 2035

11/26 12:00 pm

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

11/13 09:00 am

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know

11/13 06:15 am

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

11/11 10:50 am

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

11/08 11:46 am

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...

11/07 09:00 am

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

11/07 09:00 am

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

11/02 10:25 am

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

10/31 07:00 am

Kuick Research Highlights Explosive Growth and M&A Momentum In Global Multispecific Antibody Market

10/31 06:01 am

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

10/30 08:00 am

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

10/28 09:13 am

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

10/17 08:00 am

3 Stocks to Buy and Hold Ahead of Upcoming Earnings

10/16 12:32 pm

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

10/15 07:00 am

Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

10/14 01:00 pm

Why Scholar Rock Stock Got Socked on Monday

10/13 05:22 pm

Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss

10/13 01:24 pm

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

10/12 10:18 am

2 Beaten-Down Stocks to Buy and Hold for a Decade

09/30 07:30 am

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

09/25 09:52 am

Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight

09/22 01:00 pm

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision

09/22 12:07 pm

Communiqué de presse : Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP

09/22 12:30 am

Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

09/22 12:30 am

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

09/22 12:29 am

Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

09/16 12:29 pm

Biotech Sector May Flip to Market Leader by Year-End

09/15 01:25 pm

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

09/09 05:46 pm

Basal Cell Carcinoma Treatment Market to Reach USD 9.01 Billion by 2034, Reports Towards Healthcare

09/09 10:00 am

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

09/09 07:00 am

With Asthma-Related ER Visits Increasing, AAFA Names 2025 Asthma Capitals

09/09 07:00 am

What's Happening With Regeneron Pharmaceuticals Stock On Monday?

09/08 01:11 pm

2 Beaten-Down Stocks to Buy on the Dip

09/07 09:15 am

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

08/27 04:59 am

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

08/27 04:50 am

Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight

08/26 01:00 pm

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

08/26 07:00 am

Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™

08/18 10:00 am

Regeneron (REGN) Q2 EPS Jumps 53%

08/02 06:09 am

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

08/01 09:22 am

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.

07/19 06:09 am

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape

07/14 04:47 am